Safety and Effectiveness of Empagliflozin in Korean Patients with Type 2 Diabetes Mellitus: Results from a Nationwide Post-Marketing Surveillance.

Jun Sung Moon,Nam Hoon Kim,Jin Oh Na,Jae Hyoung Cho,In-Kyung Jeong,Soon Hee Lee,Ji-Oh Mok,Nan Hee Kim,Dong Jin Chung,Jinhong Cho,Dong Woo Lee,Sun Woo Lee,Kyu Chang Won

Diabetes & metabolism journal（2023）

引用 2|浏览7

暂无评分

摘要

Empagliflozin is a safe and potent glucose-lowering drug in routine use among Korean patients with type 2 diabetes mellitus. It is expected to have better glycemic efficacy in Korean patients with poorly controlled type 2 diabetes mellitus.

查看译文

关键词

Diabetes mellitus, type 2,Empagliflozin,Hypoglycemic agents,Product surveillance, postmarketing,Sodium-glucose transporter 2 inhibitors

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要